Other formats:
BibTeX
LaTeX
RIS
@article{1673717,
author = {NovakovaandJiresova, Alena and Kopeckova, Katerina and Boublikova, Ludmila and Chloupková, Renata and Melichar, Bohuslav and Petruzelka, Lubos and Finek, Jindrich and Fiala, Ondrej and Grell, Peter and Batko, Stanislav and Linke, Zdenek and Kiss, Igor and Prausova, Jana and Büchler, Tomáš},
article_location = {ALBANY},
article_number = {2020},
doi = {http://dx.doi.org/10.2147/CMAR.S255332},
keywords = {colorectal cancer; regorafenib; registry; survival; outcome analysis},
language = {eng},
issn = {1179-1322},
journal = {CANCER MANAGEMENT AND RESEARCH},
title = {Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients},
url = {https://www.dovepress.com/front_end/cr_data/cache/pdf/download_1597040957_5f30e93d90283/cmar-255332-regorafenib-for-metastatic-colorectal-cancer-an-analysis-of.pdf},
volume = {12},
year = {2020}
}
TY - JOUR
ID - 1673717
AU - Novakova-Jiresova, Alena - Kopeckova, Katerina - Boublikova, Ludmila - Chloupková, Renata - Melichar, Bohuslav - Petruzelka, Lubos - Finek, Jindrich - Fiala, Ondrej - Grell, Peter - Batko, Stanislav - Linke, Zdenek - Kiss, Igor - Prausova, Jana - Büchler, Tomáš
PY - 2020
TI - Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients
JF - CANCER MANAGEMENT AND RESEARCH
VL - 12
IS - 2020
SP - 5365-5372
EP - 5365-5372
PB - DOVE MEDICAL PRESS LTD
SN - 11791322
KW - colorectal cancer
KW - regorafenib
KW - registry
KW - survival
KW - outcome analysis
UR - https://www.dovepress.com/front_end/cr_data/cache/pdf/download_1597040957_5f30e93d90283/cmar-255332-regorafenib-for-metastatic-colorectal-cancer-an-analysis-of.pdf
L2 - https://www.dovepress.com/front_end/cr_data/cache/pdf/download_1597040957_5f30e93d90283/cmar-255332-regorafenib-for-metastatic-colorectal-cancer-an-analysis-of.pdf
N2 - Purpose: Regorafenib is an oral multikinase inhibitor approved for the therapy of previously treated metastatic colorectal carcinoma (mCRC). The aim of the present study was to analyze the outcomes of treatment with regorafenib in real-world clinical practice based on data from a national registry. Methods: The CORECT registry, the Czech non-interventional database of patients with mCRC treated with targeted agents, searched for patients with metastatic CRC treated with regorafenib. In total, 555 evaluable patients were identified. Results: The median age at diagnosis was 61.7 years. All patients had disease progression on or after previous systemic treatment. Most patients were treated with an initial dose of 160 mg daily (n = 463; 83.6%). The median duration of treatment was 2.7 months (range 0.023.4 months). By the data cut-off date, 472 patients (85%) had completed treatment with regorafenib and were evaluable for treatment response evaluation. Partial response was reported in 13 patients (2.8%) and disease stabilization in 130 patients (27.5%). Median progression-free survival (PFS) and overall survival (OS) were 3.5 months (95% confidence interval [CI] 3.2-3.7 months) and 9.3 months (95% CI 8.3-10.3 months), respectively. The 6-month OS rate was 67.7% (95% CI 63.4-72.1%). Multivariable analysis showed that female gender, longer interval from diagnosis of metastatic disease, MO stage at diagnosis, and Eastern Cooperative Oncology Group performance status (ECOG PS) 0 were associated with longer PFS, while higher body-mass index (BMI), longer interval from diagnosis of metastatic disease, and ECOG PS of 0 were associated with longer OS. Conclusion: OS of patients treated with regorafenib in the real-world clinical practice in this cohort exceeded that reported in randomized trials. Regorafenib is a safe and active treatment option for a subgroup of patients with mCRC who are progressing after other systemic therapies and maintain good performance status.
ER -
NOVAKOVA-JIRESOVA, Alena, Katerina KOPECKOVA, Ludmila BOUBLIKOVA, Renata CHLOUPKOVÁ, Bohuslav MELICHAR, Lubos PETRUZELKA, Jindrich FINEK, Ondrej FIALA, Peter GRELL, Stanislav BATKO, Zdenek LINKE, Igor KISS, Jana PRAUSOVA and Tomáš BÜCHLER. Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients. \textit{CANCER MANAGEMENT AND RESEARCH}. ALBANY: DOVE MEDICAL PRESS LTD, 2020, vol.~12, No~2020, p.~5365-5372. ISSN~1179-1322. Available from: https://dx.doi.org/10.2147/CMAR.S255332.
|
